BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 26103617)

  • 21. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
    Sarin H
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
    Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
    CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendrimer advances for the central nervous system delivery of therapeutics.
    Xu L; Zhang H; Wu Y
    ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-based nanocarriers for CNS-targeted drug delivery.
    Micheli MR; Bova R; Magini A; Polidoro M; Emiliani C
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):71-86. PubMed ID: 22283231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS.
    Silva GA
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S4. PubMed ID: 19091001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.
    Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X
    Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-assembled amphiphilic core-shell nanocarriers in line with the modern strategies for brain delivery.
    Elezaby RS; Gad HA; Metwally AA; Geneidi AS; Awad GA
    J Control Release; 2017 Sep; 261():43-61. PubMed ID: 28648865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
    Crawford L; Rosch J; Putnam D
    J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
    Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
    CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.
    Deo AK; Theil FP; Nicolas JM
    Mol Pharm; 2013 May; 10(5):1581-95. PubMed ID: 23256608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing the capacity of cell-penetrating peptides for drug delivery to the central nervous system.
    Kang T; Gao X; Chen J
    Curr Pharm Biotechnol; 2014; 15(3):220-30. PubMed ID: 24938893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug delivery to the CNS and polymeric nanoparticulate carriers.
    Costantino L
    Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for drug delivery to the central nervous system by systemic route.
    Kasinathan N; Jagani HV; Alex AT; Volety SM; Rao JV
    Drug Deliv; 2015 May; 22(3):243-57. PubMed ID: 24471801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanotechnology in Neurosciences: An Approach.
    Bustos Cruz RH; Sanchez MM; Dominguez-Sanchez MA; Barreto GE; Lancheros D; Reynolds J
    Curr Pharm Des; 2017; 23(28):4154-4169. PubMed ID: 28814235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents.
    Biddlestone-Thorpe L; Marchi N; Guo K; Ghosh C; Janigro D; Valerie K; Yang H
    Adv Drug Deliv Rev; 2012 May; 64(7):605-13. PubMed ID: 22178615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.
    Shahjin F; Chand S; Yelamanchili SV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):443-458. PubMed ID: 31485884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
    Al-Ahmady ZS
    Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics.
    Bourganis V; Kammona O; Alexopoulos A; Kiparissides C
    Eur J Pharm Biopharm; 2018 Jul; 128():337-362. PubMed ID: 29733950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.